Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics' stock price has been impacted by several events in the past six months. Q1 2025 earnings missed EPS and revenue forecasts, leading to a stock drop. Q2 2025 earnings also missed EPS forecasts due to OEM channel weakness, despite growth in regenerative solutions revenue. The full market release of the Integrity™ Implant System showed strong initial interest. Anika announced the sale of its Arthrosurface business and the intention to divest Parcus Medical. Q3 2025 earnings reported a positive EPS against a forecasted loss, driven by commercial channel revenue increase, but OEM revenue continued to decline. The company announced a $15 million share repurchase program. Overall, the stock experienced a significant decline of 46.64% between November 21, 2024, and November 20, 2025.

Specific information regarding the demand seasonality for Anika Therapeutics, Inc.'s products and services is not explicitly provided in the search results. One source mentions that historical insights can be used to identify seasonal patterns in monthly returns for ANIK stock, but does not detail product demand seasonality.

Anika Therapeutics, Inc. is a global, integrated orthopedic and regenerative medicines company specializing in therapeutic products focused on early intervention orthopedic care, addressing degenerative orthopedic diseases and traumatic conditions. The company's major products are based on its proprietary hyaluronic acid (HA) technology. Key offerings include injectable viscosupplements for osteoarthritis pain management, regenerative solutions like the Integrity™ Implant System and Tactoset®, and other applications such as advanced wound care, surgical adhesion prevention, dermal applications, ophthalmic products, and veterinary visco-supplementation.

Anika Therapeutics is headquartered in Bedford, Massachusetts, United States, and maintains a global presence. The company derives a majority of its revenue from the United States and has a presence in Europe and other countries. Products are distributed through direct subsidiaries and a network of distributors across North America, Europe, Latin America, the Middle East, and Asia.

Information specifically detailing Anika Therapeutics, Inc.'s brand reputation in the past year is not readily available in the provided search results. However, analyst ratings generally indicate a "Moderate Buy" consensus for the stock.

Anika Therapeutics is primarily owned by institutional shareholders, who hold approximately 84.82% of the stock. Insiders own about 18.48%, and retail investors hold 0.00%. Another source indicates institutional investors hold approximately 40.81%, insiders 4.25%, and public companies and individual investors 11.01%. Major institutional owners include BlackRock Inc., Trigran Investments Inc., Caligan Partners LP, Vanguard Group Inc., Acadian Asset Management LLC, and Dimensional Fund Advisors LP. The largest individual shareholder is Farmaceutici Spa Fidia.